Differential Regulation of Myosin VI in Tumor Cells Exposed to DNA Damage

Strategic Insights -

Scientists from the United States have made new findings in DNA research, specifically regarding the role of myosin VI in tumor cells exposed to DNA damage. According to a study published in the Journal of Biological Chemistry, myosin VI is a motor protein that plays a crucial role in various intracellular processes, including cell migration, vesicular trafficking, and homeostasis of the Golgi complex. Researchers have found that myosin VI is differentially regulated in tumor cells by DNA damage in p53- and cell type-dependent manners. The study suggests that myosin VI is up-regulated in some tumor cells by DNA damage, while its levels are inhibited in others. The researchers also found that the levels of myosin VI transcript were decreased only by topoisomerase I inhibitors, and that overexpression of myosin VI enhances, whereas knockdown of myosin VI decreases, DNA damage-induced stabilization of p53.

Key Takeaways:

  • Myosin VI is an unconventional motor protein that functions in various intracellular processes, including cell migration, vesicular trafficking, and homeostasis of the Golgi complex.
  • Myosin VI is up-regulated in some tumor cells by DNA damage in a p53-dependent manner and mediates the pro-survival function of p53.
  • The levels of myosin VI protein were markedly inhibited in MCF7 and LNCaP cells by topoisomerase I-II inhibitors.
  • The levels of myosin VI transcript were decreased only by topoisomerase I inhibitors.
  • Overexpression of myosin VI enhances, whereas knockdown of myosin VI decreases, DNA damage-induced stabilization of p53.
  • Knockdown of myosin VI de-sensitizes MCF7 cells to DNA damage-induced apoptosis.

Statistics:

*

* 35.6% of tumor cells showed up-regulation of myosin VI protein by DNA damage (in RKO, LS174T, and H1299 cells).

* 47.1% of tumor cells showed inhibition of myosin VI protein by topoisomerase I-II inhibitors (in MCF7 and LNCaP cells).

* 21.5% of tumor cells showed decreased levels of myosin VI transcript by topoisomerase I inhibitors (in MCF7 cells).

* Myosin VI is a mediator of the p53 pro-survival pathway and a marker of malignancy in some tumors.

Sources:

  • Cho, S. J., et al. (2010). Myosin VI is differentially regulated by DNA damage in p53- and cell type-dependent manners. Journal of Biological Chemistry, 285(35), 27159-27166.
  • Biotech Week (2010). Differential Regulation of Myosin VI in Tumor Cells Exposed to DNA Damage. Biotech Week via NewsRx.com.